Works matching DE "SODIUM-glucose cotransporters"
Results: 1882
Analysis of the Endocrine Responses to Anti-Diabetes Drugs: An Issue of Elevated Plasma Renin Concentration in Sodium-Glucose Co-Transporter 2 Inhibitor.
- Published in:
- International Journal of General Medicine, 2025, v. 18, p. 135, doi. 10.2147/IJGM.S497664
- By:
- Publication type:
- Article
EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE.
- Published in:
- Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi, 2025, v. 88, n. 1, p. 45, doi. 10.26650/IUITFD.1508775
- By:
- Publication type:
- Article
SGLT2 Inhibitors: The First Endothelial-Protector for Diabetic Nephropathy.
- Published in:
- Journal of Clinical Medicine, 2025, v. 14, n. 4, p. 1241, doi. 10.3390/jcm14041241
- By:
- Publication type:
- Article
Examining the results of cardiovascular outcome trials.
- Published in:
- Practice Nursing, 2019, v. 30, n. 2, p. 87, doi. 10.12968/pnur.2019.30.2.87
- By:
- Publication type:
- Article
New pharmacological approaches to diabetes management.
- Published in:
- Practice Nursing, 2015, v. 26, n. 3, p. 140, doi. 10.12968/pnur.2015.26.3.140
- By:
- Publication type:
- Article
Current updates of sodium-glucose cotransporter-2 inhibitor effects on atherosclerosis: a systematic review and meta-analysis of randomized controlled trial.
- Published in:
- Acta Angiologica, 2024, v. 30, n. 1, p. 1, doi. 10.5603/aa.98562
- By:
- Publication type:
- Article
Comment on "Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients".
- Published in:
- Cardiovascular Drugs & Therapy, 2024, v. 38, n. 1, p. 201, doi. 10.1007/s10557-023-07527-z
- By:
- Publication type:
- Article
Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
- Published in:
- Cardiovascular Drugs & Therapy, 2023, v. 37, n. 3, p. 561, doi. 10.1007/s10557-022-07319-x
- By:
- Publication type:
- Article
Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 6, p. 1187, doi. 10.1007/s10557-021-07257-0
- By:
- Publication type:
- Article
Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
- Published in:
- Cardiovascular Drugs & Therapy, 2022, v. 36, n. 3, p. 497, doi. 10.1007/s10557-021-07234-7
- By:
- Publication type:
- Article
Protection of the kidney with sodium-glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials.
- Published in:
- Clinical & Experimental Nephrology, 2019, v. 23, n. 3, p. 304, doi. 10.1007/s10157-018-1673-0
- By:
- Publication type:
- Article
Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2024, v. 40, n. 3, p. 1, doi. 10.1002/dmrr.3784
- By:
- Publication type:
- Article
A meta‐analysis of randomized controlled trials evaluating sodium‐glucose co‐transporter 2 inhibitors and incidental atrial fibrillation—Is there a true benefit?
- Published in:
- Diabetes/Metabolism Research & Reviews, 2024, v. 40, n. 1, p. 1, doi. 10.1002/dmrr.3715
- By:
- Publication type:
- Article
Dapagliflozin improves pancreatic islet function by attenuating microvascular endothelial dysfunction in type 2 diabetes.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2023, v. 39, n. 3, p. 1, doi. 10.1002/dmrr.3607
- By:
- Publication type:
- Article
Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2021, v. 37, n. 6, p. 1, doi. 10.1002/dmrr.3413
- By:
- Publication type:
- Article
Managing type 2 diabetes mellitus during COVID‐19 pandemic: The bittersweet.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2021, v. 37, n. 1, p. 1, doi. 10.1002/dmrr.3360
- By:
- Publication type:
- Article
Poor adherence and persistence to sodium glucose co‐transporter 2 inhibitors in real‐world settings: Evidence from a systematic review and meta‐analysis.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2021, v. 37, n. 1, p. 1, doi. 10.1002/dmrr.3350
- By:
- Publication type:
- Article
Long-term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Mechanistic evaluation of the effect of sodium‐dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
- Published in:
- Biopharmaceutics & Drug Disposition, 2020, v. 41, n. 8/9, p. 352, doi. 10.1002/bdd.2253
- By:
- Publication type:
- Article
The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?
- Published in:
- Journal of Membrane Biology, 2021, v. 254, n. 5/6, p. 513, doi. 10.1007/s00232-021-00192-z
- By:
- Publication type:
- Article
De Novo Expression of Sodium-Glucose Cotransporter SGLT2 in Bowman's Capsule Coincides with Replacement of Parietal Epithelial Cell Layer with Proximal Tubule-like Epithelium.
- Published in:
- Journal of Membrane Biology, 2014, v. 247, n. 8, p. 675, doi. 10.1007/s00232-014-9686-4
- By:
- Publication type:
- Article
Effect of SGLT2 Inhibitors on Risk of Stroke in Diabetes: A Meta-Analysis.
- Published in:
- Cerebrovascular Diseases, 2022, v. 51, n. 5, p. 585, doi. 10.1159/000521782
- By:
- Publication type:
- Article
Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders.
- Published in:
- Biotechnology & Applied Biochemistry, 2016, v. 63, n. 1, p. 145, doi. 10.1002/bab.1319
- By:
- Publication type:
- Article
Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy.
- Published in:
- Glycobiology, 2017, v. 27, n. 8, p. 691, doi. 10.1093/glycob/cwx047
- By:
- Publication type:
- Article
Predictors Of Kidney Function Outcomes In Type 2 Diabetes Mellitus Patients With Chronic Heart Failure Treated With Dapagliflosin.
- Published in:
- E Journal of Cardiovascular Medicine, 2023, v. 11, p. 1
- By:
- Publication type:
- Article
Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease.
- Published in:
- Egyptian Journal of Internal Medicine, 2024, v. 36, n. 1, p. 1, doi. 10.1186/s43162-024-00352-2
- By:
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences (England, Scotland and Wales).
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 6, p. 175
- Publication type:
- Article
Drugs in development and new data on established drugs: Highlights from the American Diabetes Association 81st Scientific Sessions.
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 4, p. 115
- Publication type:
- Article
News from the Diabetes UK Professional Conference 2021. Part 1.
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 3, p. 75
- Publication type:
- Article
HOW TO USE SGLT2 INHIBITORS SAFELY AND EFFECTIVELY.
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 1, p. 5
- Publication type:
- Article
Smoking and COVID-19: Unravelling the risks and signposting resources.
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 1, p. 1
- By:
- Publication type:
- Article
News from the 2020 EASD Annual Meeting.
- Published in:
- Diabetes & Primary Care, 2020, v. 22, n. 5, p. 115
- By:
- Publication type:
- Article
A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe.
- Published in:
- Diabetes & Primary Care, 2020, v. 22, n. 3, p. 1
- By:
- Publication type:
- Article
Ketones and diabetes.
- Published in:
- Diabetes & Primary Care, 2020, v. 22, n. 3, p. 49
- Publication type:
- Article
SGLT2 inhibitors and their association with balanoposthitis and Fournier's gangrene.
- Published in:
- Diabetes & Primary Care, 2020, v. 22, n. 2, p. 31
- By:
- Publication type:
- Article
The management of hyperglycaemia in people with diabetes and chronic kidney disease: A GPnotebook Shortcut.
- Published in:
- Diabetes & Primary Care, 2020, v. 22, n. 1, p. 13
- Publication type:
- Article
Diabetes and kidney disease. Part 2: management.
- Published in:
- Diabetes & Primary Care, 2019, v. 21, n. 5, p. 153
- By:
- Publication type:
- Article
The 2019 ESC/EASD guidelines: Comprehensive and controversial.
- Published in:
- Diabetes & Primary Care, 2019, v. 21, n. 5, p. 145
- By:
- Publication type:
- Article
Why NICE needs to change: Defining a new prescribing pathway.
- Published in:
- Diabetes & Primary Care, 2019, v. 21, n. 1, p. 33
- By:
- Publication type:
- Article
HOW TO USE SGLT2 INHIBITORS SAFELY.
- Published in:
- Diabetes & Primary Care, 2018, v. 20, n. 5, p. 173
- Publication type:
- Article
ADA/EASD DRAFT CONSENSUS GUIDELINE.
- Published in:
- Diabetes & Primary Care, 2018, v. 20, n. 3, p. 105
- Publication type:
- Article
OBSERVE-4D.
- Published in:
- Diabetes & Primary Care, 2018, v. 20, n. 3, p. 102
- By:
- Publication type:
- Article
The SIGN 154 diabetes guideline and primary care: it's not just about the glucose.
- Published in:
- Diabetes & Primary Care, 2018, v. 20, n. 2, p. 75
- By:
- Publication type:
- Article
Sodium--glucose cotransporter 2 inhibitors: Emerging evidence and changes in guidance.
- Published in:
- Diabetes & Primary Care, 2017, v. 19, n. 5, p. 210
- By:
- Publication type:
- Article
Updates from the ADA conference, the NHS RightCare diabetes pathway and more.
- Published in:
- Diabetes & Primary Care, 2017, v. 19, n. 3, p. 98
- Publication type:
- Article
QOF, toe amputation risk, heart failure drug, and preventing type 1 diabetes.
- Published in:
- Diabetes & Primary Care, 2017, v. 19, n. 2, p. 54
- By:
- Publication type:
- Article
Preventing diabetic ketoacidosis: Bridging the gap between primary and secondary care.
- Published in:
- Diabetes & Primary Care, 2016, v. 18, n. 4, p. 179
- By:
- Publication type:
- Article